Influenza A virus continuously infects humans and the antigenic shifts of this respiratory virus
enable it to cross the species barrier, threatening public health with the risk of pandemics …

Background Human antibodies that interfere with the biological activity of haemagglutinins
(HAs) of influenza viruses have high potential as an antiviral agent. Methods Human single …

Seasonal influenza viruses are highly contagious, leading to 290,000–650,000 mortalities
every year globally. Among the influenza viruses, influenza A virus (H3N2) has attracted …

The discovery of broadly neutralizing monoclonal antibodies against influenza viruses has
raised hope for the successful development of new antiviral drugs. However, due to the …

Influenza virus causes acute respiratory infection in humans, and is a major public health
concern globally. Antibodies play a central role in host protection against influenza virus. We …

Cross-reactive neutralizing antibodies against influenza A viruses have received attention
for their potentials for prophylactic and therapeutic. These antibodies usually bind to …

Influenza remains a global health risk and challenge. Currently, neuraminidase (NA)
inhibitors are extensively used to treat influenza, but their efficacy is compromised by the …

The pandemic threat posed by emerging zoonotic influenza A viruses necessitates
development of antiviral agents effective against various antigenic subtypes. Human …

Seasonal epidemics caused by antigenic variations in influenza A virus remain a public
health concern and an economic burden. The isolation and characterization of broadly …

Due to continuous changes to its antigenic regions, influenza viruses can evade immune
detection and cause a significant amount of morbidity and mortality around the world …